| |
Telaprevir/Peginterferon/Ribavirin
|
| |
| |
Reported by Jules Levin
5th International Workshop on Hepatitis C, Resistance and New Compounds
June24-25, 2010, Boston MA
Tara L Kieffer, DJ Bartels, JC Sullivan, EZ Zhang, AM Tigges, JL Dorrian, and AD Kwong, Vertex Pharmaceuticals Incorporated, Cambridge MA, USA
"TVR should be stopped upon detection of breakthrough (stopping rules at week 4)"
1McHutchison JG, et al. N Engl J Med 2009;360:1827-1838; 2Hˇzode C, et al. N Engl J Med 2009;360:1839-1850
1McHutchison JG, et al. N Engl J Med 2009;360:1827-1838; 2Hˇzode C, et al. N Engl J Med 2009;360:1839-1850;
3McHutchison JG, et al. N EnglJ Med 2010; 362:1292-1303; 4Shiffman ML, et al. Hepatology 2008;48 (Suppl 4):1135A
"TVR should be stopped upon detection of breakthrough (stopping rules at week 4)"
|
|
| |
| |
|
|
|
